Inovio Pharmaceuticals Inc (NASDAQ:INO) CEO Jong Joseph Kim sold 100,000 shares of the firm’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $21.13, for a total transaction of $2,113,000.00. Following the transaction, the chief executive officer now directly owns 1,188,313 shares of the company’s stock, valued at approximately $25,109,053.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ INO opened at $19.44 on Friday. Inovio Pharmaceuticals Inc has a twelve month low of $1.91 and a twelve month high of $33.79. The firm has a fifty day simple moving average of $21.82 and a 200 day simple moving average of $11.64. The company has a debt-to-equity ratio of 0.51, a current ratio of 8.53 and a quick ratio of 8.53.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.04). Inovio Pharmaceuticals had a negative net margin of 4,700.42% and a negative return on equity of 166.85%. The company had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.55 million. During the same period last year, the firm posted ($0.30) earnings per share. As a group, research analysts anticipate that Inovio Pharmaceuticals Inc will post -0.77 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN increased its stake in Inovio Pharmaceuticals by 1.0% in the first quarter. Wells Fargo & Company MN now owns 81,892 shares of the biopharmaceutical company’s stock valued at $609,000 after purchasing an additional 790 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Inovio Pharmaceuticals by 78.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 182,771 shares of the biopharmaceutical company’s stock valued at $603,000 after purchasing an additional 80,574 shares in the last quarter. Raymond James & Associates increased its stake in Inovio Pharmaceuticals by 22.5% in the fourth quarter. Raymond James & Associates now owns 22,163 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 4,075 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Inovio Pharmaceuticals by 67.3% in the first quarter. Nuveen Asset Management LLC now owns 555,677 shares of the biopharmaceutical company’s stock valued at $4,134,000 after purchasing an additional 223,563 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Inovio Pharmaceuticals by 24.7% in the first quarter. Geode Capital Management LLC now owns 1,684,463 shares of the biopharmaceutical company’s stock valued at $12,532,000 after purchasing an additional 333,382 shares in the last quarter. 27.80% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently issued reports on INO. ValuEngine downgraded shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Maxim Group downgraded shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating and set a $24.00 price target for the company. in a research note on Wednesday, July 1st. Benchmark reaffirmed a “buy” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, June 30th. HC Wainwright downgraded shares of Inovio Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Finally, Cantor Fitzgerald lifted their target price on shares of Inovio Pharmaceuticals from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.33.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Recommended Story: Understanding Analyst Ratings

Insider Buying and Selling by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.